PROMOTE Study: Prediction of Response Of HorMOnal Treatment in Advanced and Recurrent Endometrial Cancer

What this Trial Is About

The PROMOTE study focuses on women with advanced stage (FIGO stage III and IV) or recurrent endometrial cancer. Researchers aim to improve how hormonal therapy is used by analyzing tumor tissue taken before treatment to better predict which patients may respond. This is important because hormonal therapy is less aggressive and better tolerated than chemotherapy, but current use relies heavily on physician experience rather than detailed molecular criteria. Participants are women planned to receive hormonal therapy for their advanced or recurrent endometrial cancer. The study observes these patients as they undergo hormonal treatment without altering their care. Tumor biopsies taken within 120 days before starting therapy are analyzed to correlate molecular features with treatment response. The study does not involve additional experimental treatments but collects clinical and molecular data during usual care. During the study, participants' responses to hormonal therapy are tracked over two years, measuring response rate, progression-free survival, and clinical benefit. Quality of life is also assessed over six months. Researchers collect information from biopsies and monitor health outcomes without adding extra interventions. The study runs from October 2022 until September 2027, allowing long-term follow-up of participants' treatment outcomes and quality of life.

PROMOTE Study: Prediction of Response Of HorMOnal Treatment in Advanced and Recurrent Endometrial Cancer